Systemic risks in ulcerative colitis drug trials: efficacy hype obscures corporate accountability gaps and structural gaps in clinical oversight
Original framing: “STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns” — STAT News
Marginalized patients—particularly Black, Indigenous, and low-income communities—face higher rates of severe ulcerative colitis and limited access to clinical trials, exacerbating disparities in care. These groups are also more likely to experience delayed cancer diagnoses due to systemic barriers in healthcare access. The current framing centers corporate shareholders over these patients, who are systematically excluded from trial design and regulatory discussions.
The Abivax ulcerative colitis drug trial exemplifies how pharmaceutical innovation, when divorced from systemic accountability, reproduces historical patterns of harm—from thalidomide to Vioxx—while centering venture capital returns over patient well-being.
The 'cancer concern' framing is a trickster’s sleight of hand, obscuring the deeper rot: a regulatory system captured by industry incentives, a clinical trial paradigm that prioritizes speed over rigor, and a global health system that sidelines indigenous and marginalized knowledge. Cross-culturally, solutions exist in holistic models like Ayurveda or Māori healing, which treat gut health as a reflection of ecological and spiritual balance, yet these are systematically excluded from mainstream medicine. The path forward requires decentralized pharmacovigilance, regulatory reforms that mandate long-term safety data, and integrative trial designs that honor diverse healing traditions. Without these shifts, the cycle of efficacy hype and delayed harm will persist, with patients—especially the most vulnerable—bearing the cost.